Table 2. Mean daily doses and cumulative exposure by treatment arm.

		3 Months			6 Months
		ALMS		AURA-LV/AURORA 1	ALMS		AURA-LV/AURORA 1
		IVC(n=91)	MMF(n=88)	Voclosporin(N=179)	IVC(n=91)	MMF(n=88)	Voclosporin(N=179)
Oral GC*	n†Daily dose, mean (SD), mg/dayCumulative dose, mean (SD), mg	n=8921.6 (6.1)2964.8 (648.4)	n=8121.5 (5.1)2850.9 (592.3)	n=1696.6 (5.5)1104.0 (336.1)	n=569.7 (2.8)3799.2 (927.5)	n=6110.0 (1.8)3666.9 (854.1)	n=1595.2 (11.0)1485.9 (752.2)
MMF	n†Daily dose, mean (SD), g/dayCumulative dose, mean (SD), g	n/a	n=812.7 (0.6)205.1 (48.5)	n=1651.9 (0.5)149.9 (42.1)	n/a	n=692.8 (0.4)397.6 (130.1)	n=1611.9 (0.6)295.1 (94.9)

Propensity score methodology was used to generate two groups of matched participants (n=179) from the ALMS (IVC and MMF) and AURA-LV/AURORA 1 (voclosporin) studies based on the following parameters: age, duration of lupus nephritis, duration of SLE, albumin, C3, C4, creatinine, anti-dsDNA, eGFR, UPCR, biopsy class, sex, and geographical region. Mean daily dose is the average daily dose of all participants with data available at the specified time point (3 or 6 months) including doses of 0 mg mg. Mean cumulative dose is an average of drug exposure for all participants in each arm regardless of overall treatment duration.

^*Only includes oral glucocorticoidGCs; doses of intravenous methylprednisolone included at the beginning of AURA-LV and AURORA-1 are not included.

^†Participants with data available at the respective time point.

ALMSAspreva Lupus Management StudyC, complement; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; GC, glucocorticoid; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; n/a, not applicable; SLE, systemic lupus erythematosusUPCRurine protein creatinine ratio